Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
| ▸ | MMP10 | P09238 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6608461 | 0.92 | CYP2A6 (0.38) | MMP2MMP13CYP2A6MMP1MMP3 | |
| SCHEMBL6403067 | 0.92 | CYP2A6 (0.38) | MMP2MMP13CYP2A6MMP1MMP3 | |
| SCHEMBL6607301 | 0.88 | CYP2A6 (0.41) | MMP2MMP13CYP2A6TRPV3TPSAB1 | |
| SCHEMBL6607282 | 0.82 | CYP2A6 (0.33) | MMP2MMP13CYP2A6TPSAB1 | |
| SCHEMBL6608267 | 0.82 | CYP2A6 (0.40) | MMP2MMP13CYP2A6MMP14TPSAB1 | |
| SCHEMBL6608264 | 0.82 | CYP2A6 (0.40) | MMP2MMP13CYP2A6MMP14TPSAB1 | |
| SCHEMBL6400023 | 0.79 | MMP2 (0.38) | MMP2MMP13TRPV3MMP1MMP3 | |
| SCHEMBL6399305 | 0.78 | CYP2A6 (0.36) | MMP2MMP13CYP2A6TPSAB1 | |
| SCHEMBL6399773 | 0.77 | CYP2A6 (0.43) | MMP2MMP13CYP2A6TPSAB1 | |
| SCHEMBL6400628 | 0.77 | CYP2A6 (0.43) | MMP2MMP13CYP2A6TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | MMP2 2846/4885MMP13 559/4885CYP2A6 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.